Thalassemia

Thalassemia is a group of autosomal recessive hemoglobinopathies characterized by reduced or absent production of normal alpha- or beta-globin chains, leading to ineffective erythropoiesis and chronic hemolytic anemia.[1][2] The resultant compensatory erythroid hyperplasia drives massive expansion of bone marrow spaces throughout the skeleton, including the jaws and craniofacial bones, producing characteristic skeletal deformities and distinctive radiographic changes.[2][3] In the jaws, the signature imaging pattern consists of diffusely enlarged medullary spaces with coarsened or absent trabeculation, thinned cortices, attenuated lamina dura, and small or obliterated maxillary sinuses.[4][5] Management centers on regular blood transfusions, iron chelation therapy, and multidisciplinary coordination for dental and orthodontic care.[2][6]

The current clinical classification divides thalassemia into alpha-thalassemia and beta-thalassemia based on the affected globin-chain gene.[2] A functional classification separates patients into transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT).[7]

• Beta-thalassemia major (also called Cooley's anemia) is the severe, transfusion-dependent form most commonly associated with craniofacial and jaw changes.[1][8]
• Beta-thalassemia intermedia produces a milder phenotype with variable transfusion needs.[7]
• Beta-thalassemia minor (beta-thalassemia trait) is the heterozygous carrier state and is clinically asymptomatic.[7]
• Mediterranean anemia and erythroblastic anemia are older synonyms that remain in occasional use.[1]
• The characteristic facial appearance has been termed "Cooley's facies" or "thalassemia facies".[6]

Hemoglobinopathies are the most common monogenic disorders worldwide.[7] Approximately 1.5% of the global population carries a beta-thalassemia allele and 5% carries an alpha-thalassemia allele.[7] Prevalence is highest across a belt extending from sub-Saharan Africa through the Mediterranean, the Middle East, the Indian subcontinent, and Southeast Asia, reflecting the evolutionary advantage of the carrier state against malaria.[2][7] Population migrations have introduced thalassemia to non-endemic regions including northern Europe and North America.[2] Beta-thalassemia major typically presents in infancy with progressive anemia in the first months of life.[8] Craniofacial and jaw changes are most pronounced in inadequately transfused children and become established during the first decade.[1][8] Both sexes are equally affected.

Systemic presentation

Infants with beta-thalassemia major are well at birth but develop progressive anemia, pallor, jaundice, and hepatosplenomegaly within the first six months of life.[1][8] Inadequately transfused children develop stunted growth, skeletal deformities, and pathologic fractures.[8][9] Iron overload from chronic transfusions causes endocrine dysfunction (hypogonadism, growth hormone deficiency, diabetes), cardiac siderosis, and liver disease.[2][10]

Craniofacial findings

Compensatory marrow expansion in the facial and cranial bones produces the characteristic thalassemia facies: frontal and parietal bossing, depressed nasal bridge, prominent malar eminences, and maxillary overgrowth with forward displacement of the upper incisors.[1][6] These changes lead to Class II malocclusion, increased overjet, anterior open bite, flaring and spacing of maxillary anterior teeth, and difficulties with speech and mastication.[6]

Oral findings

• Pallor of the gingiva and oral mucosa[6]
• Tooth discoloration from iron deposition secondary to chronic transfusions[6]
• Increased caries experience[11]
• Delayed development and eruption of the dentition[6]
• Parotid gland swelling and atrophic candidiasis (occasional)[6]
• Splenectomized patients carry elevated infection risk from bacteremia following invasive dental procedures[3][6]

The radiographic changes of thalassemia in the jaws result from erythroid marrow hyperplasia and are most pronounced in beta-thalassemia major, particularly in inadequately transfused patients.[4][5] Findings are characteristically bilateral and diffuse.

Location and distribution

Changes affect both the maxilla and mandible diffusely. The maxilla is often more severely involved owing to its greater proportion of cancellous bone and marrow-containing spaces.[4][5] The calvarium and facial bones are affected concurrently; the classic "hair-on-end" pattern of perpendicular trabecular striations in the skull vault is a characteristic radiographic hallmark of the disease, though it is now rarely seen in well-transfused patients.[5][12][13]

Internal architecture

• Enlarged bone marrow spaces with coarsened, widely spaced trabeculae are a common and reliable finding. The normal fine trabecular pattern is replaced by a coarse, sparse network reflecting marrow expansion.[4][6]
• Generalized osteopenia of the jaws is characteristic, with a ground-glass or granular appearance of the medullary bone.[5][9]
• A "lamellated" skull pattern—parallel osseous lamellae within the diploic space—has been described as an occasional variant in poorly transfused patients.[13]

Periphery and cortical involvement

• Thinned cortex of the mandible, particularly at the inferior border, is a common finding.[4][14]
• Attenuated or absent lamina dura around the teeth is characteristic.[4]
• The inferior alveolar nerve canal may appear faint or indistinguishable from the surrounding rarefied bone.[4]
• Reduced mandibular cortical width and panoramic mandibular index values have been demonstrated on panoramic radiographs.[14]

Effects on teeth and adjacent structures

• Short roots with reduced crown-body length are common; the mandibular first molar is characteristically affected.[4]
• Spiky-shaped (tapered) roots are a reliable diagnostic feature.[4]
• Taurodontism is significantly more prevalent than in unaffected controls.[4]
• Delayed dental development and eruption, reduced tooth size, and diminished dental arch dimensions are common.[6]

Maxillary sinus changes

• Small or obliterated maxillary sinuses are characteristic, resulting from marrow expansion into the sinus walls with delayed pneumatization.[4][15]
• CT studies demonstrate significantly increased thickness of all maxillary sinus bony walls, with the greatest thickening at the posterior and lateral walls.[15][16]
• Sinus volume is reduced compared to age-matched controls, and the thickened walls may mimic or obscure mucosal disease, complicating the radiologic diagnosis of sinusitis.[16][17]
• CBCT volumetric assessment confirms a tendency toward lower maxillary sinus volumes and surface areas, with an associated Class II skeletal pattern.[18]

Maxillary expansion and skeletal pattern

Overgrowth of the maxilla produces anterior and lateral bony prominence with forward displacement of the premaxilla.[1][19] Cephalometric analysis typically reveals increased ANB angle consistent with a skeletal Class II relationship and increased lower facial height.[18][19]

MRI — bone marrow signal and iron quantification

MRI demonstrates diffuse marrow signal abnormalities reflecting both hyperplastic red marrow and transfusional iron deposition.[20][21] In untreated patients, T1-weighted images show diffuse low-to-intermediate signal throughout the axial and appendicular skeleton consistent with red marrow reconversion.[21] In transfused patients, iron deposition causes marked hypointensity on T2*-weighted gradient-echo sequences; this pattern was observed in the majority of transfused beta-thalassemia major patients in one series.[20] The distribution of iron deposition follows active red marrow sites and retreats centrally with age.[21] Marrow signal on T2*-weighted sequences correlates with splenic siderosis and serum ferritin levels.[20] Quantitative T2* mapping of the liver and heart is the established non-invasive standard for monitoring systemic iron overload and guiding chelation therapy.[2][22]

MRI — craniofacial

Sagittal MRI of the skull may reveal marked expansion of the diploic space with obliteration of the paranasal sinuses by hyperplastic marrow tissue.[23]

CT — maxillary sinus and facial skeleton

Medical CT demonstrates thickened maxillary sinus walls, reduced sinus volume and density, and narrowed posterior choanae in beta-thalassemia patients.[15][16] These anatomic alterations increase the risk of chronic rhinosinusitis and may confound radiologic interpretation of sinus disease.[16][17]

The diffuse jaw changes of thalassemia must be distinguished from other conditions that produce generalized marrow expansion, osteopenia, or altered trabecular architecture in the jaws. Clinical history, laboratory findings, and the bilateral, symmetric nature of the changes are key to narrowing the differential.

The highest-risk diagnostic pitfall is failing to recognize the jaw changes of thalassemia in a patient without a known hematologic diagnosis, particularly in non-endemic regions. The combination of diffuse marrow expansion, thinned cortices, attenuated lamina dura, small maxillary sinuses, and characteristic dental anomalies (short spiky roots, taurodontism) should prompt hematologic evaluation including complete blood count and hemoglobin electrophoresis.[1][4]

The skeletal changes in thalassemia are driven by erythroid hyperplasia within the bone marrow. Marrow biopsy demonstrates a markedly hypercellular marrow with a decreased myeloid-to-erythroid ratio, reflecting massive expansion of erythroid precursors attempting to compensate for ineffective erythropoiesis.[3] Erythroid dysmaturation and increased apoptosis of early red cell precursors are characteristic.[7]

Bone remodeling

The expanding marrow physically displaces and resorbs cortical and trabecular bone, producing the thinned cortices and widened medullary spaces seen radiographically.[2][3] Increased osteoclast activity and elevated bone turnover contribute to osteopenia and low bone mass.[10] In the skull, periosteal osteoblastic reactions to sinusoidal neovascularization associated with marrow hyperplasia may produce the lamellated osseous pattern.[13]

Iron deposition

In transfused patients, hemosiderin deposits accumulate in the bone marrow, liver, spleen, heart, and endocrine organs.[3][27] Iron deposition in the gingiva and teeth contributes to the clinical finding of tooth discoloration.[6] Prussian blue staining of marrow biopsy specimens demonstrates increased iron stores.[28]

Radiologic-pathologic correlation

The radiographic findings of enlarged marrow spaces, thinned cortices, and coarsened trabeculae directly correspond to the histologic picture of erythroid hyperplasia replacing normal fatty marrow and resorbing surrounding bone.[3][4] The degree of skeletal change correlates with the severity of anemia and the adequacy of transfusion therapy; well-transfused patients show suppressed marrow hyperplasia and less pronounced skeletal deformity.[2][8]

Systemic management

Treatment is determined by clinical severity. Patients with TDT require regular red blood cell transfusions (typically every 2–5 weeks) to maintain pretransfusion hemoglobin levels of 9–10.5 g/dL, which suppresses ineffective erythropoiesis and limits marrow expansion.[1][2] Iron chelation therapy is initiated when serum ferritin exceeds 1,000 ng/mL (TDT) or 800 ng/mL (NTDT), using deferoxamine, deferiprone, or deferasirox as monotherapy or in combination.[2][29] Monitoring of hepatic and cardiac iron burden by MRI guides chelation dose adjustment.[2] Hematopoietic stem cell transplantation is curative in selected patients, and luspatercept is approved for anemia in transfusion-dependent beta-thalassemia.[1][30] Hydroxyurea may reduce transfusion frequency in some patients.[1]

Dental and orthodontic management

• Conservative dental care with early intervention for caries is recommended to avoid complex procedures such as endodontic therapy or extractions.[6]
• Prophylactic antibiotic coverage is recommended before extractions or minor oral surgery, particularly in splenectomized patients who carry elevated infection risk.[6]
• Patients receiving bisphosphonate therapy for thalassemia-related bone loss are at increased risk of medication-related osteonecrosis of the jaw; extractions should be avoided when possible.[6]
• Orthodontic treatment should employ lighter forces and shorter monitoring intervals because thinned cortical bone may accelerate tooth movement.[6]
• Early interceptive orthodontics with functional and extraoral appliances can reduce the severity of developing craniofacial deformity in growing children.[6][19]

Surgical management

In advanced maxillary deformity, orthognathic surgery—including Le Fort I osteotomy, premaxillary segmental repositioning, and bilateral sagittal split osteotomy—may be required.[6][19] Surgical